JP2022535417A5 - - Google Patents
Info
- Publication number
- JP2022535417A5 JP2022535417A5 JP2021571944A JP2021571944A JP2022535417A5 JP 2022535417 A5 JP2022535417 A5 JP 2022535417A5 JP 2021571944 A JP2021571944 A JP 2021571944A JP 2021571944 A JP2021571944 A JP 2021571944A JP 2022535417 A5 JP2022535417 A5 JP 2022535417A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857194P | 2019-06-04 | 2019-06-04 | |
| US62/857,194 | 2019-06-04 | ||
| US201962867577P | 2019-06-27 | 2019-06-27 | |
| US62/867,577 | 2019-06-27 | ||
| US202063032292P | 2020-05-29 | 2020-05-29 | |
| US63/032,292 | 2020-05-29 | ||
| PCT/US2020/035703 WO2020247372A1 (en) | 2019-06-04 | 2020-06-02 | Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535417A JP2022535417A (ja) | 2022-08-08 |
| JP2022535417A5 true JP2022535417A5 (https=) | 2023-06-12 |
| JPWO2020247372A5 JPWO2020247372A5 (https=) | 2023-06-12 |
Family
ID=73653315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571944A Pending JP2022535417A (ja) | 2019-06-04 | 2020-06-02 | 骨髄細胞炎症性表現型を調節するための抗ｓｉｇｌｅｃ－９組成物及び方法、ならびにその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220396627A1 (https=) |
| EP (1) | EP3980462A4 (https=) |
| JP (1) | JP2022535417A (https=) |
| KR (1) | KR20220042056A (https=) |
| CN (1) | CN114401991A (https=) |
| AU (1) | AU2020288824A1 (https=) |
| BR (1) | BR112021024314A2 (https=) |
| CA (1) | CA3142433A1 (https=) |
| IL (1) | IL288511A (https=) |
| TW (1) | TW202110890A (https=) |
| WO (1) | WO2020247372A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11987612B2 (en) | 2019-11-04 | 2024-05-21 | Alector Llc | Siglec-9 ECD fusion molecules |
| AU2021329884A1 (en) * | 2020-08-17 | 2023-02-16 | SURGE Therapeutics, Inc. | Immune modulation of myeloid derived suppressive cell function for cancer treatment |
| WO2023192993A2 (en) * | 2022-03-31 | 2023-10-05 | The Wistar Institute Of Anatomy And Biology | Antibodies against human siglec-7 and use thereof for immunotherapy |
| US20250215078A1 (en) * | 2022-03-31 | 2025-07-03 | The Wistar Institute Of Anatomy And Biology | Antibodies Against Human Siglec-9 and Use Thereof for Immunotherapy |
| WO2024054527A1 (en) * | 2022-09-06 | 2024-03-14 | The Research Institute At Nationwide Children's Hospital | Genetically engineered bone marrow derived myeloid cells for treatment of central nervous system tumors |
| AU2023411024A1 (en) * | 2022-12-23 | 2025-08-07 | The Wistar Institute Of Anatomy And Biology | Siglec 9 inhibitors and methods of use thereof for enhancing immunotherapy efficacy |
| CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
| CN117741143B (zh) * | 2024-02-20 | 2024-05-07 | 首都医科大学附属北京地坛医院 | Siglec-9蛋白及其特异性抗体在制备神经梅毒或神经损伤诊断产品中的应用 |
| CN121281695B (zh) * | 2025-12-11 | 2026-03-31 | 山东师范大学 | 用于药物发现的分子生成方法、系统、介质及设备 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001352977A (ja) * | 2000-06-12 | 2001-12-25 | Kirin Brewery Co Ltd | 樹状細胞（ＤＣ）膜分子Ｓｉｇｌｅｃ−９に対する抗体、並びにそれを用いたＤＣ検出法及びＤＣ分離法 |
| CN101035807A (zh) * | 2004-06-09 | 2007-09-12 | 泰勒公司 | Siglec－6相关疾病的诊断和治疗 |
| GB0521991D0 (en) * | 2005-10-28 | 2005-12-07 | Univ Dundee | Siglec-9 binding agents |
| CA3003458A1 (en) * | 2015-10-29 | 2017-05-04 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
| WO2017123745A1 (en) * | 2016-01-12 | 2017-07-20 | Palleon Pharma Inc. | Use of siglec-7 or siglec-9 antibodies for the treatment of cancer |
| GB201611535D0 (en) * | 2016-07-01 | 2016-08-17 | King S College London | Methods and compositions for treating cancer with siglec-9 activity modulators |
| AU2018298676A1 (en) * | 2017-07-10 | 2019-12-19 | Innate Pharma | Siglec-9-neutralizing antibodies |
-
2020
- 2020-06-02 CN CN202080056075.5A patent/CN114401991A/zh active Pending
- 2020-06-02 EP EP20818538.9A patent/EP3980462A4/en not_active Withdrawn
- 2020-06-02 KR KR1020217040139A patent/KR20220042056A/ko not_active Ceased
- 2020-06-02 AU AU2020288824A patent/AU2020288824A1/en not_active Abandoned
- 2020-06-02 JP JP2021571944A patent/JP2022535417A/ja active Pending
- 2020-06-02 TW TW109118528A patent/TW202110890A/zh unknown
- 2020-06-02 BR BR112021024314A patent/BR112021024314A2/pt not_active IP Right Cessation
- 2020-06-02 WO PCT/US2020/035703 patent/WO2020247372A1/en not_active Ceased
- 2020-06-02 CA CA3142433A patent/CA3142433A1/en active Pending
- 2020-06-02 US US17/615,861 patent/US20220396627A1/en not_active Abandoned
-
2021
- 2021-11-29 IL IL288511A patent/IL288511A/en unknown